Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy

The document reviewed various therapeutic approaches for chronic central serous chorioretinopathy (CSCR). Treatments included photodynamic therapy (PDT), intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, and mineralocorticoid receptor antagonists. PDT, particularly with verteporfin, showed efficacy in reducing subretinal fluid and improving visual acuity. Anti-VEGF treatments like bevacizumab were also effective but less consistently. Mineralocorticoid receptor antagonists, such as eplerenone, demonstrated potential benefits in managing CSCR. The review highlighted the need for individualized treatment plans based on patient-specific factors and disease characteristics.